Download PDF
Thromb Haemost 1991; 66(01): 141-152
DOI: 10.1055/s-0038-1646383
Review Article
Schattauer GmbH Stuttgart

Hirudin and Derivatives as Anticoagulant Agents

F Markwardt
Further Information

Publication History

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Markwardt F. Untersuchungen über Hirudin. Naturwissenschaften. 1955; 42: 537-38
    PubMedGoogle Scholar
  • 2 Markwardt F. Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins. Naunyn Schmiedebergs Arch. Pharmacol. 1956; 229: 389-99
    CrossrefPubMedGoogle Scholar
  • 3 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe-Seylers Z. Physiol. Chem. 1957; 308: 147-56
    PubMedGoogle Scholar
  • 4 Markwardt F, Walsmann P. Die Reaktion zwischen Hirudin und Thrombin. Hoppe-Seylers Z. Physiol. Chem. 1958; 312: 85-98
    PubMedGoogle Scholar
  • 5 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombininhibitors Hirudin. Hoppe Seylers Z. Physiol. Chem. 1967; 348: 1381-86
    CrossrefPubMedGoogle Scholar
  • 6 Bagdy D, Barabas E, Graf L, Peterson TE, Magnusson S. Hirudin. Methods Enzymol. 1976; 45: 669-78
    PubMedGoogle Scholar
  • 7 Dodt J, Seemüller U, Maschler R, Fritz H. The complete covalent structure of hirudin. Localization of the disulfide bonds. Biol. Chem. Hoppe Seyler. 1985; 366: 379-85
    PubMedGoogle Scholar
  • 8 Baskova IP, Cherkesova DU, Mosolov VV. Hirudin from leech heads and whole leeches and 'pseudo'-hirudin from leech bodies. Thrombos. Res. 1983; 30: 459-67
    CrossrefPubMedGoogle Scholar
  • 9 Dodt J, Machleidt W, Seemüller U, Maschler R, Fritz H. Isolation and charcterization of hirudin isoinhibitors and sequence analysis of hirudin PA. Biol. Chem. Hoppe Seyler. 1986; 367: 803-11
    CrossrefPubMedGoogle Scholar
  • 10 Scharf M, Engels J, Tripier D. Primary structure of new iso-hirudins. FEBS Lett. 1989; 255: 105-10
    CrossrefPubMedGoogle Scholar
  • 11 Môrki WE, Grossenbacher H, Grütter MG, Liersch MH, Meyhack B, Heim J. Recombinant hirudin: Genetic engineering and structure analysis. Semin. Thromb. Hemost. 1991; 17: 88-93
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Markwardt F. Versuche zur pharmakologischen Charakterisierung des Hirudins. Naunyn Schmiedebergs Arch Pharmacol. 1958; 234: 516-29
    PubMedGoogle Scholar
  • 13 Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol. 1970; 19: 924-32
    PubMedGoogle Scholar
  • 14 Rydel TJ, Ravichandran KG, Tulinski A, Bode W, Huber R, Roitsch C, Fenton II JW. The structure of a complex of recombinant hirudin and human α-thrombin. Science. 1990; 249: 277-80
    CrossrefPubMedGoogle Scholar
  • 15 Stürzebecher J, Walsmann P. Structure-activity relationships of recombinant hirudins. Semin. Thromb. Hemost. 1991; 17: 94-98
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton II JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990; 29: 7095-7101
    CrossrefPubMedGoogle Scholar
  • 17 Walsmann P. Über den Einsatz des spezifischen Thrombin-Inhibitors Hirudin für diagnostische und biochemische Untersuchungen. Pharmazie. 1988; 43: 737-44
    PubMedGoogle Scholar
  • 18 Stocker K. Laboratory use of hirudin. Semin. Thromb. Hemost. 1991; 17: 113-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 1986; 25: 4622-28
    CrossrefPubMedGoogle Scholar
  • 20 Markwardt F. Die antagonistische Wirkung des Hirudins gegen Thrombin in vivo. Naturwissenschaften. 1956; 43: 11
    CrossrefPubMedGoogle Scholar
  • 21 Walsmann P, Markwardt F. Biochemische und pharmakologische Aspekte des Thrombininhibitors Hirudin. Pharmazie. 1981; 36: 653-60
    PubMedGoogle Scholar
  • 22 Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb. Haemost. 1982; 47: 226-29
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent. Biomed. Biochim. Acta. 1985; 44: 1007-13
    PubMedGoogle Scholar
  • 24 Markwardt F. Hirudin, der blutgerinnungshemmende Wirkstoff des medizinischen Blutegels. Blut. 1958; 4: 161-70
    CrossrefPubMedGoogle Scholar
  • 25 Markwardt F. Biochemistry and pharmacology of hirudin. in: Pirkle H, Markland jr. FS. (eds) Hemostasis and animal venoms.. Dekker, New York, Basel: 1988. pp 255-69
    Google Scholar
  • 26 Markwardt F. The comeback of hirudin - an old-established anticoagulant agent. Folia Haematol. 1988; 115: 10-23
    PubMedGoogle Scholar
  • 27 Markwardt F. Development of hirudin as an antithrombotic agent. Semin. Thromb. Hemost. 1989; 15: 269-82
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Markwardt F. Past, present and future of hirudin. Haemostasis. 1991; 21 (suppl 1) 11-26
    PubMedGoogle Scholar
  • 29 Hoet B, Close P, Vermylen J, Verstraete M. Hirudo medicinalis and hirudin. In: Recent Advances in Blood Coagulation.. Poller L. (ed) Vol 3, Publ. Churchill Livingstone: 1990. pp 223-44
    Google Scholar
  • 30 Walsmann P, Kaiser B. Biochemical and pharmacological properties of recombinant hirudin. Drugs of Today. 1989; 25: 473-85
    PubMedGoogle Scholar
  • 31 Walenga JM, Pifarre R, Fareed J. Recombinant hirudin as antithrombotic agent. Drugs of the Future. 1990; 15: 267-80
    PubMedGoogle Scholar
  • 32 Fareed J, Walenga JM, Hoppensteadt D, Pifarre R. Development perspectives for recombinant hirudin as an antithrombotic agent. Biol. Clin. Hematol. 1989; 11: 143-52
    PubMedGoogle Scholar
  • 33 Kawabata SL, Morita T, Kaida S, Igarashi H, Iwanaga S. Difference in enzymatic properties between staphylothrombin and free α-thrombin. Ann. N.Y. Acad. Sci. 1980; 485: 27-40
    PubMedGoogle Scholar
  • 34 Markwardt F. Der Hirudintoleranztest. Klin. Wschr. 1959; 37: 1142-43
    CrossrefPubMedGoogle Scholar
  • 35 Schmutzler R, Markwardt F. Der Hirudintest, eine Mikromethode zur Kontrolle des Prothrombinspiegels bei der Antikoagulantientherapie. Klin. Wschr. 1962; 40: 796-98
    CrossrefPubMedGoogle Scholar
  • 36 Markwardt F. Die Bestimmung des Thrombins durch Titration mit Hirudin. Arch. Pharmaz. 1957; 290: 280-84
    CrossrefPubMedGoogle Scholar
  • 37 Markwardt F. Hirudin - Biochemisch-pharmakologische Wirkung und Anwendung zur gerinnungsphysiologischen Diagnostik. in: Marx R, Thies HA. (eds) Kontrolle von Antithrombotika,. Basel, Editiones Roche: 1980. pp. 105-15
    Google Scholar
  • 38 Griessbach U, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb. Res. 1985; 37: 347-50
    CrossrefPubMedGoogle Scholar
  • 39 Markwardt F, Stürzebecher J, Walsmann P. The hirudin standard. Thromb. Res. 1990; 59: 395-400
    CrossrefPubMedGoogle Scholar
  • 40 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb. Haemost. 1990; 64: 464-68
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Hoffmann A, Markwardt F. Inhibition of the thrombin-platelet reaction by hirudin. Hemostasis. 1984; 14: 164-69
    PubMedGoogle Scholar
  • 42 Hofsteenge J, Taguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin and inhibitors. Biochem. J. 1986; 237: 243-51
    CrossrefPubMedGoogle Scholar
  • 43 Hauptmann J, Brüggener E, Markwardt F. Effect of heparin, hirudin and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. Hemostasis. 1987; 17: 321-28
    PubMedGoogle Scholar
  • 44 Markwardt F, Hoffmann A, Stürzebecher J. Influence of thrombin inhibitors on the thrombin-induced activation of human blood platelets. Hemostasis. 1983; 13: 227-33
    PubMedGoogle Scholar
  • 45 Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Hemostasis. 1990; 20: 112-18
    PubMedGoogle Scholar
  • 46 Glusa E. Hirudin and platelets. Semin Thromb. Hemost. 1991; 17: 122-25
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Basic-Micic M, Krupinski K, Breddin HK. r-hirudin effects on various platelet functions. Angio. Arch. 1989; 18: 1
    PubMedGoogle Scholar
  • 48 Markwardt F, Stürzebecher J, Glusa E. Antithrombin effects of native and recombinant hirudins. Biomed. Biochim. Acta. 1990; 49: 399-404
    PubMedGoogle Scholar
  • 49 Glusa E, Markwardt F. Adrenaline-induced reactions of human platelets in hirudin plasma. Hemostasis. 1980; 9: 188-92
    PubMedGoogle Scholar
  • 50 Shuman MA. Thrombin-cellular interaction. Ann. N.Y. Acad. Sci. 1986; 485: 228-39
    CrossrefPubMedGoogle Scholar
  • 51 Markwardt F jr, Franke T, Glusa E, Nilius B. Pharmacological modification of mechanical and electrical responses of frog heart to thrombin. Naunyn-Schmiedebergs Arch. Pharmac. 1990; 341: 341-46
    PubMedGoogle Scholar
  • 52 Van Obberghen-Schilling E, Perez-Rodriguez R, Pouyssegur J. Hirudin, a probe to analyze the growth promoting activity of thrombin in fibroblasts; reevaluation of the temporal action of competence factors. Biochem. Biophys. Res. Commun. 1982; 105: 79-86
    PubMedGoogle Scholar
  • 53 Glusa E, Markwardt F. Studies on thrombin-induced endothelium-dependent vascular effects. Biomed Biochim Acta. 1988; 47: 623-30
    PubMedGoogle Scholar
  • 54 Walenga JM, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Comparative studies on various assays for the laboratory evaluation of r-hirudin. Semin. Thromb. Hemost. 1991; 17: 103-12
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Stürzebecher J. Methods for determination of hirudin. Semin. Thromb. Hemost. 1991; 17: 99-102
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Spannagl M, Bichler J, Lill L, Schramm W, Fritz H. A fast chromogenic assay for determination of hirudin in plasma (abstract). Thromb. Hemost. 1989; 62: 32
    PubMedGoogle Scholar
  • 57 Richter M, Walsmann P, Cyranka U, Markwardt F. 125-1 Markierung von Hirudin. Pharmazie. 1986; 41: 52
    PubMedGoogle Scholar
  • 58 Bichler J, Fichtl B, Siebeck M, Fritz H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzneim.-Forsch. 1988; 38: 704-10
    PubMedGoogle Scholar
  • 59 Spinner S, Stöffler G, Fink E. Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin. J. Immunol. Methods. 1986; 87: 79-93
    CrossrefPubMedGoogle Scholar
  • 60 Schlaeppi JM, Vekemans S, Rink H, Chang JY. Preparation of monoclonal antibodies to hirudin and hirudin peptides. Eur. J. Biochem. 1990; 188: 463-70
    CrossrefPubMedGoogle Scholar
  • 61 Spinner S, Scheffauer F, Maschler R, Stöffler G. A hirudin catching ELISA for quantitating the anticoagulant in biological fluids. Thrombos. Res. 1980; 51: 617-25
    PubMedGoogle Scholar
  • 62 Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb. Haemost. 1982; 47: 226-29
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Markwardt F, Nowak G, Stürzebecher U, Walsmann P. Studies on the pharmacokinetics of hirudin. Biomed. Biochim. Acta. 1987; 46: 237-44
    PubMedGoogle Scholar
  • 64 Nowak G. Pharmacokinetics of hirudin. Semin. Thromb. Hemost. 1991; 17: 145-49
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Nowak G, Markwardt F, Fink E. Pharmacokinetic studies with recombinant hirudin in dogs. Folia Haematol. 1988; 115: 70-74
    PubMedGoogle Scholar
  • 66 Markwardt F, Huan XQ, Walenga JM, Münch M, Hoppensteadt D. Pharmacokinetics of recombinant hirudin in primates (abstract). Fed. Proc. 1988; 1: 48
    PubMedGoogle Scholar
  • 67 Markwardt F, Fink E, Kaiser B, Klöcking H-P, Nowak G, Richter M, Stürzebecher J. Pharmacological survey of recombinant hirudin. Pharmazie. 1988; 43: 202-07
    PubMedGoogle Scholar
  • 68 Richter M, Cyranka U, Nowak G, Walsmann P. Pharmacokinetics of 125 I-hirudin in rats and dogs. Folia Haematol. 1988; 115: 64-69
    PubMedGoogle Scholar
  • 69 Henschen A, Markwardt F, Walsmann P. Identification by HPLC analysis of the unaltered forms of hirudin and desulfated hirudin after kidney passage (abstract).. Thromb. Res. 1987; 7 (suppl) 37
    PubMedGoogle Scholar
  • 70 Henschen A, Markwardt F, Walsmann P. Evidence for the identity of hirudin isolated after kidney passage with the starting material. Folia Haematol. 1988; 115: 59-63
    PubMedGoogle Scholar
  • 71 Richter M, Walsmann P, Markwardt F. Plasma level of dextran-r-hirudin. Pharmazie. 1989; 44: 73-74
    PubMedGoogle Scholar
  • 72 Markwardt F, Richter M, Walsmann P, Riesener G, Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour. Biomed. Biochim. Acta. 1990; 49: 1103-08
    PubMedGoogle Scholar
  • 73 Markwardt F, Nowak G, Stürzebecher J, Griessbach U, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb. Haemost. 1984; 52: 160-63
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Markwardt F, Nowak G, Stürzebecher J, Vogel G. Clinico-pharmacological studies with recombinant hirudin. Thromb. Res. 1988; 52: 393-400
    CrossrefPubMedGoogle Scholar
  • 75 Markwardt F, Nowak G, Stürzebecher J. Clinical pharmacology of recombinant hirudin. Haemostasis. 1991; 21 (suppl 1) 133-36
    PubMedGoogle Scholar
  • 76 Klöcking H-P, Güttner J, Fink E, Markwardt F. Studies in toxicity of recombinant hirudin. Blut. 1990; 60: 12
    PubMedGoogle Scholar
  • 77 Klöcking H-P. Toxicology of hirudin. Semin. Thromb. Hemost. 1991; 17: 126-29
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Bichler J, Gemmerli R, Fritz H. Studies for revealing a possible sensitization to hirudin after repeated intravenous injection in baboons. Thromb. Res. 1991; 61: 39-51
    PubMedGoogle Scholar
  • 79 Kaiser B. Anticoagulant and antithrombotic actions of recombinant hirudin. Semin. Thromb. Hemost. 1991; 17: 130-36
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb. Res. 1989; 54: 377-88
    CrossrefPubMedGoogle Scholar
  • 81 Talbot MD, Ambler J, Butler KD, Findley VS, Mitchel KA, Peters RF, Tweed MF, Wallis RB. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb. Haemost. 1989; 61: 77-80
    Article in Thieme ConnectPubMedGoogle Scholar
  • 82 Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga J, Fareed J. antithrombotic activity of recombinant hirudin in the rat: A comparative study with heparin. Thromb. Res. 1989; 54: 435-45
    CrossrefPubMedGoogle Scholar
  • 83 Talbot M. Biology of recombinant hirudin (CGP 39393): A new prospect in the treatment of thrombosis. Semin. Thromb. Hemost. 1989; 15: 293-301
    Article in Thieme ConnectPubMedGoogle Scholar
  • 84 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors.. Thromb. Res. 1986; : 613-20
    PubMedGoogle Scholar
  • 85 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin. Folia Haematol. 1988; 115: 41-46
    PubMedGoogle Scholar
  • 86 Fareed J, Walenga JM. Do we need to neutralize hirudin's anticoagulant effects to minimize bleeding?. Fed. Proc. 1989; 3: A 328
    PubMedGoogle Scholar
  • 87 Fareed J, Walenga JM, Hoppensteadt D, Iyer L, Pifarre R. Neutralization of recombinant hirudin: Some practical considerations. Semin. Thromb. Hemost. 1991; 17: 137-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Brüggener E, Walsmann P, Markwardt F. Neutralization of hirudin anticoagulant action by DIP-thrombin. Pharmazie. 1989; 44: 648-49
    PubMedGoogle Scholar
  • 89 Walsmann P. Untersuchungen zur Affinitôtschromatographie von Hirudin an trôgerfixiertem Thrombin. Pharmazie. 1981; 36: 860-61
    PubMedGoogle Scholar
  • 90 Walsmann P, Markwardt F. On the isolation of the thrombin inhibitor hirudin. Thromb. Res. 1985; 40: 563-70
    CrossrefPubMedGoogle Scholar
  • 91 Bucha E, Markwardt F, Nowak G. Hirudin in haemodialysis. Thromb. Res. 1990; 60: 445-55
    CrossrefPubMedGoogle Scholar
  • 92 Markwardt F, Nowak G, Bucha E. Hirudin as anticoagulant in experimental haemodialysis.. Haemostasis 1991; 21 (suppl 1) 149-55
    PubMedGoogle Scholar
  • 93 Walenga JM, Pifarre R, Hoppensteadt D, Fareed J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: Some objective considerations. Semin. Thromb. Haemost. 1989; 15: 316-33
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Markwardt F. Prospective clinical use of hirudin as an anticoagulant. Biomed. Prog. 1990; 3: 19-23
    PubMedGoogle Scholar
  • 95 Klöcking H-P, Markwardt F. Influence of recombinant hirudin on the thrombogenicity of prothrombin complex concentrates. Pharmazie. 1989; 44: 341-42
    PubMedGoogle Scholar
  • 96 Freund M, Cazenave JP, Courtney M, Degryse E, Roitsch C, Bernat A, Delebassee D, Defreyn G, Maffrand JP. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue-factor in rats. Thromb. Haemost. 1990; 63: 187-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 97 Degryse E, Acker M, Defreyn G, Bernat A, Maffrand JP, Roitsch C, Courtney M. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin. Protein Eng. 1989; 2: 459-65
    CrossrefPubMedGoogle Scholar
  • 98 Nowak G, Markwardt F. Hirudin in disseminated intravascular coagulation.. Haemostasis. 1991; 2 (suppl 1) 142-48
    PubMedGoogle Scholar
  • 99 Nowak G, Markwardt F. Influence of hirudin on endotoxin-induced disseminated intravascular coagulation (DIC) in weaned pigs. Exp. Pathol. 1980; 18: 438-43
    PubMedGoogle Scholar
  • 100 Markwardt F, Nowak G, Hoffmann J. Comparative studies on thrombin inhibitors in experimental microthrombosis. Thromb. Haemost. 1983; 49: 235-37
    Article in Thieme ConnectPubMedGoogle Scholar
  • 101 Siebeck M, Hoffmann H, Weipert J, Spannagl M, Weis M, Bichler J. Hirudin prevents intravascular coagulation in porcine endotoxin shock. In : Chirurgisches Forum '88 f. exp. u. klin.. Forschung Schriefers. et al. (eds) 1988. Springer, Berlin-Heidelberg: pp. 297-300
    Google Scholar
  • 102 Ishikawa A, Hafter R, Seemüller U, Gokel JM, Graeff H. The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC). Thromb. Res. 1980; 19: 351-358
    CrossrefPubMedGoogle Scholar
  • 103 Hauptmann J, Brüggener E. Influence of hirudin on the consumption of antithrombin III in experimental DIC. Folia Haematol. 1988; 115: 83-87
    PubMedGoogle Scholar
  • 104 Chesebro JH, Heras M, Mruk J, Grill D, Fuster V. The critical role of thrombin in arterial thrombosis is demonstrated by hirudin.. Angio. Arch. 1989; 18: 9
    PubMedGoogle Scholar
  • 105 Krupinski K, Breddin H K, Markwardt F, Haarmann W. Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis. Haemostasis. 1989; 19: 74-82
    PubMedGoogle Scholar
  • 106 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989; 79: 657-65
    CrossrefPubMedGoogle Scholar
  • 107 Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb. Haemost. 1990; 63: 44-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 108 Bucha E, Nowak G, Markwardt F. Prevention of experimental coronary thrombosis by hirudin. Folia Haematol. 1988; 115: 52-58
    PubMedGoogle Scholar
  • 109 Markwardt F. Anticoagulants after thrombolysis;. in Schettler G. (ed) Reperfusion and revascularisation in acute myocardial infarction.. Springer, Berlin.: 1988. pp. 137-43
    Google Scholar
  • 110 Markwardt F. Prevention of coronary thrombosis by hirudin;. in Papp J Gy. (ed) Cardiovascular pharmacology '87 Budapest. ( Akademiai Kiado, Budapest: 1987. ) pp. 449-56
    Google Scholar
  • 111 Walenga JM, Bakhos M, Messmore HL, Fareed J, Pifarre R. The potential use of r-hirudin as an anticoagulant in cardiopulmonary bypass model.. Ann. Thorac. Surg. (in press)
    PubMedGoogle Scholar
  • 112 Vogel G, Markwardt F. Clinical use of hirudin. Folia Haematol. 1988; 115: 113-18
    PubMedGoogle Scholar
  • 113 Vogel G, Markwardt F. Preliminary clinical reports on the antithrombotic action of hirudin (abstract).. Thromb. Res. 1987; 7 (suppl.) 42
    PubMedGoogle Scholar
  • 114 Markwardt F. The comeback of hirudin as an antithrombotic agent. Semin. Thromb. Haemost. 1991; 17: 75-82
    PubMedGoogle Scholar